ELTX
Elicio Therapeutics, Inc.
3.42
1 x 3.34
2 x 4.28
bid
ask
-
1.72
33.56%
11:23 AM
timesize
| Ytd | -57.10% | |
| 1y | -56.50% |
3.31
day range
3.80
2.66
52 week range
16.00
| Open | 3.60 | Prev Close | 5.14 | Low | 3.31 | High | 3.80 | Mkt Cap | 65.21M |
| Vol | 2.85M | Avg Vol | 1.45M | EPS | -2.36 | P/E | N/A | Forward P/E | -1.96 |
| Beta | N/A | Short Ratio | 2.49 | Inst. Own | 5.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.65 | 200-d Avg | 9.65 | 1yr Est | 9.50 |
| Income Statement | |||
| Operating Expenses | 10.60M | ||
| Research and Development Expense | 6.76M | ||
| Selling, General and Administrative Expense | 3.85M | ||
| Operating Income | -10.60M | ||
| Interest Expense | 407.00K | ||
| Net Income | -11.82M | ||
| Net Income Common Stock | -11.82M | ||
| Net Income Common Stock (USD) | -11.82M | ||
| Consolidated Income | -11.82M | ||
| Earnings per Basic Share | -0.65 | ||
| Earnings per Basic Share (USD) | -0.65 | ||
| Earnings per Diluted Share | -0.65 | ||
| Earning Before Interest & Taxes (EBIT) | -11.42M | ||
| Earning Before Interest & Taxes (USD) | -11.42M | ||
| Weighted Average Shares | 18.21M | ||
| Weighted Average Shares Diluted | 18.21M | ||
| Balance Sheet | |||
| Cash and Equivalents | 14.95M | ||
| Cash and Equivalents (USD) | 14.95M | ||
| Current Assets | 16.20M | ||
| Property, Plant & Equipment Net | 4.79M | ||
| Total Assets | 22.69M | ||
| Debt Current | 1.04M | ||
| Total Debt | 14.34M | ||
| Current Liabilities | 7.23M | ||
| Debt Non-Current | 13.30M | ||
| Total Liabilities | 24.13M | ||
| Accumulated Retained Earnings (Deficit) | -245.49M | ||
| Accumulated Other Comprehensive Income | -122.00K | ||
| Shareholders Equity | -1.44M | ||
| Shareholders Equity (USD) | -1.44M | ||
| Assets Non-Current | 6.49M | ||
| Total Debt (USD) | 14.34M | ||
| Liabilities Non-Current | 16.90M | ||
| Trade and Non-Trade Payables | 272.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 289.00K | ||
| Net Cash Flow from Financing | 8.03M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -3.61M | ||
| Issuance (Purchase) of Equity Shares | 8.03M | ||
| Net Cash Flow from Operations | -11.64M | ||
| Effect of Exchange Rate Changes on Cash | 5.00K | ||
| Share Based Compensation | 868.00K | ||